Related Experiment Video
Updated: Jun 18, 2026
07:00
A Laser-induced Mouse Model of Chronic Ocular Hypertension to Characterize Visual Defects
Published on: August 14, 2013
Early treatment study of elevated intraocular pressure (2)
D L Epstein1, J H Krug, E Hertzmark
1Dr. J. H. Krug, Jr., at Charlotte Eye Associates, 2620 E. 7th St., Suite 300, Charlotte, NC 28204, U.S.A.
Journal of Glaucoma
|November 19, 2009
Summary
Topical timolol therapy may prevent or delay glaucomatous damage in ocular hypertensive individuals. This finding aids clinical decisions for managing elevated intraocular pressure without optic nerve or visual field damage.
Area of Science:
- Ophthalmology
- Clinical Trials
- Glaucoma Research
Background:
- Ocular hypertension is a risk factor for glaucoma.
- Early intervention may prevent vision loss.
- Management decisions for ocular hypertension require evidence-based strategies.
Purpose of the Study:
- To evaluate the efficacy of topical timolol in preventing glaucomatous damage.
- To provide data for clinical decision-making in ocular hypertension management.
- To assess the long-term effects of timolol on ocular hypertensive patients.
Main Methods:
- Randomized, long-term clinical trial.
- Inclusion of ocular hypertensive subjects with normal optic discs and visual fields.
- Administration of topical timolol therapy.
Main Results:
- Timolol therapy demonstrated effectiveness in delaying or preventing glaucomatous damage.
- The study provided crucial data on the prophylactic use of timolol.
- Long-term follow-up confirmed the benefits of the intervention.
Conclusions:
- Topical timolol is effective in managing ocular hypertension.
- This therapy can prevent or delay the onset of glaucoma.
- Clinicians can confidently use timolol for patients with elevated intraocular pressure.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
01:14Increased Intracranial Pressure l: Introduction
Intracranial hypertension is a sustained elevation of intracranial pressure (ICP) above 22 mm Hg. In supine adults, normal ICP is ~7–15 mm Hg.The rigid, nonexpandable cranium contains three components—brain tissue, blood, and cerebrospinal fluid (CSF)—that total ~1,700 mL in a typical adult: 1,400 mL brain (~80%), 150 mL blood (~10%), and 150 mL CSF (~10%). According to the Monro–Kellie doctrine, total intracranial volume is effectively fixed. When one component expands, CSF and venous blood...